RU2009107085A - Способы, композиции и изделия, способствующие лечению рака - Google Patents
Способы, композиции и изделия, способствующие лечению рака Download PDFInfo
- Publication number
- RU2009107085A RU2009107085A RU2009107085/14A RU2009107085A RU2009107085A RU 2009107085 A RU2009107085 A RU 2009107085A RU 2009107085/14 A RU2009107085/14 A RU 2009107085/14A RU 2009107085 A RU2009107085 A RU 2009107085A RU 2009107085 A RU2009107085 A RU 2009107085A
- Authority
- RU
- Russia
- Prior art keywords
- chemotherapeutic agent
- agonist
- tumor
- combinations
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
1. Способ, способствующий лечению рака, включающий введение агониста эндотелина B (ETB) и химиотерапевтического агента. ! 2. Способ по п.1, в котором указанный рак представляет собой солидную опухоль. ! 3. Способ по п.2, в котором указанную солидную опухоль выбирают из группы, состоящей из: опухоли яичников, опухоли толстой кишки, саркомы Капоши, опухоли молочной железы, меланомы, опухоли предстательной железы, менингиомы, опухоли печени, листовидной опухоли молочной железы и их комбинации. ! 4. Способ по п.1, в котором указанный агонист ETB выбирают из группы, состоящей из: ET-1, ET-2, ET-3, BQ3020, IRL1620 (N-suc-[Glu9,Ala11,15]ET-1(8-21)), сарафотоксина 56c, [Ala1,3,11,15]ET-1 и их комбинации. ! 5. Способ по п.1, в котором указанный химиотерапевтический агент выбирают из группы, состоящей из: адриамицина, камптотецина, карбоплатина, цисплатина, даунорубицина, доксорубицина, альфа-интерферона, бета-интерферона, гамма-интерферона, интерлейкина 2, иринотекана, доцетаксела, паклитаксела, топотекана, 5-фторурацила и их комбинации. ! 6. Способ по п.2, в котором указанный агонист ETB селективно увеличивает снабжение кровью указанной солидной опухоли. ! 7. Способ по п.6, в котором указанное увеличение указанного снабжения кровью указанной опухоли увеличивает доставку указанного химиотерапевтического агента в указанную солидную опухоль. ! 8. Способ по п.1, в котором указанный агонист ETB и указанный химиотерапевтический агент вводят, по существу, одновременно. ! 9. Способ по п.8, в котором указанный агонист ETB и указанный химиотерапевтический агент вводят в виде одной композиции. ! 10. Способ по п.1, в котором указанный агонист ETB и указанный химиотерапевтический агент вводят последов�
Claims (20)
1. Способ, способствующий лечению рака, включающий введение агониста эндотелина B (ETB) и химиотерапевтического агента.
2. Способ по п.1, в котором указанный рак представляет собой солидную опухоль.
3. Способ по п.2, в котором указанную солидную опухоль выбирают из группы, состоящей из: опухоли яичников, опухоли толстой кишки, саркомы Капоши, опухоли молочной железы, меланомы, опухоли предстательной железы, менингиомы, опухоли печени, листовидной опухоли молочной железы и их комбинации.
4. Способ по п.1, в котором указанный агонист ETB выбирают из группы, состоящей из: ET-1, ET-2, ET-3, BQ3020, IRL1620 (N-suc-[Glu9,Ala11,15]ET-1(8-21)), сарафотоксина 56c, [Ala1,3,11,15]ET-1 и их комбинации.
5. Способ по п.1, в котором указанный химиотерапевтический агент выбирают из группы, состоящей из: адриамицина, камптотецина, карбоплатина, цисплатина, даунорубицина, доксорубицина, альфа-интерферона, бета-интерферона, гамма-интерферона, интерлейкина 2, иринотекана, доцетаксела, паклитаксела, топотекана, 5-фторурацила и их комбинации.
6. Способ по п.2, в котором указанный агонист ETB селективно увеличивает снабжение кровью указанной солидной опухоли.
7. Способ по п.6, в котором указанное увеличение указанного снабжения кровью указанной опухоли увеличивает доставку указанного химиотерапевтического агента в указанную солидную опухоль.
8. Способ по п.1, в котором указанный агонист ETB и указанный химиотерапевтический агент вводят, по существу, одновременно.
9. Способ по п.8, в котором указанный агонист ETB и указанный химиотерапевтический агент вводят в виде одной композиции.
10. Способ по п.1, в котором указанный агонист ETB и указанный химиотерапевтический агент вводят последовательно.
11. Способ по п.10, в котором указанный химиотерапевтический агент вводят перед указанным агонистом ETB, или указанный агонист ETB вводят перед указанным химиотерапевтическим агентом.
12. Композиция, содержащая химиотерапевтический агент, агонист ETB и необязательный наполнитель.
13. Изделие, содержащее композицию, содержащую агонист ETB и инструкцию по введению указанной композиции с химиотерапевтическим агентом для лечения солидной опухоли.
14. Изделие по п.13, дополнительно содержащее указанный химиотерапевтический агент.
15. Изделие по п.14, в котором указанный агонист ETB и указанный химиотерапевтический агент являются частью одной и той же композиции, находятся в виде отдельных композиций или являются и тем, и другим.
16. Изделие по п.14, в котором указанный агонист ETB выбирают из группы, состоящей из: ET-1, ET-2, ET-3, BQ3020, IRL1620 (N-suc-[Glu9,Ala11,15]ET-1(8-21)), сарафотоксина 56c, [Ala1,3,11,15]ET-1 и их комбинации.
17. Изделие по п.14, в котором указанный агонист ETB представляет собой IRL1620.
18. Изделие по п.14, в котором указанный химиотерапевтический агент выбирают из группы, состоящей из: адриамицина, камптотецина, карбоплатина, цисплатина, даунорубицина, доксорубицина, альфа-интерферона, бета-интерферона, гамма-интерферона, интерлейкина 2, иринотекана, доцетаксела, паклитаксела, топотекана, 5-фторурацила и их комбинации.
19. Изделие по п.14, в котором указанный химиотерапевтический агент представляет собой паклитаксел.
20. Изделие по п.14, в котором агонист ETB представляет собой IRL1620, а указанный химиотерапевтический агент выбирают из группы, состоящей из паклитаксела, доксорубицина, 5-фторурацила и их комбинации.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/461,961 | 2006-08-02 | ||
US11/461,961 US20070032422A1 (en) | 2002-10-24 | 2006-08-02 | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009107085A true RU2009107085A (ru) | 2010-09-10 |
RU2407527C2 RU2407527C2 (ru) | 2010-12-27 |
Family
ID=38752363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009107085/14A RU2407527C2 (ru) | 2006-08-02 | 2007-07-20 | Способы, композиции и изделия, способствующие лечению рака |
Country Status (18)
Country | Link |
---|---|
US (4) | US20070032422A1 (ru) |
EP (2) | EP2046323B1 (ru) |
JP (1) | JP2009545609A (ru) |
KR (1) | KR101507178B1 (ru) |
CN (1) | CN101522186B (ru) |
AR (1) | AR062177A1 (ru) |
BR (1) | BRPI0715521A2 (ru) |
CA (1) | CA2658340C (ru) |
DK (1) | DK2046323T3 (ru) |
ES (1) | ES2402232T3 (ru) |
HK (1) | HK1129601A1 (ru) |
IL (1) | IL196825A (ru) |
MX (1) | MX2009001233A (ru) |
NO (1) | NO20090915L (ru) |
RU (1) | RU2407527C2 (ru) |
TW (1) | TWI469776B (ru) |
WO (1) | WO2008016793A2 (ru) |
ZA (1) | ZA200900017B (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
JP5306208B2 (ja) | 2006-08-31 | 2013-10-02 | スペクトラム ファーマシューティカルズ インコーポレイテッド | エンドセリンアゴニストの投与による放射線療法への腫瘍細胞の感作 |
US8623823B2 (en) * | 2007-08-21 | 2014-01-07 | Midwestern University | Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist |
US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
WO2017191843A1 (ja) * | 2016-05-06 | 2017-11-09 | 一般財団法人バイオダイナミックス研究所 | 高分子化薬物含有医薬組成物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5550110A (en) * | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
CA2135151A1 (en) | 1993-11-08 | 1995-05-09 | Mitsuhiro Wakimasu | Cyclic hexapeptides, their production and use |
US5811416A (en) * | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
CA2206119C (en) | 1994-12-12 | 2008-05-13 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
US6251861B1 (en) | 1996-06-27 | 2001-06-26 | Takeda Chemical Industries, Ltd. | Treatment of cerebral infarction using cyclic hexapeptides |
CA2268640A1 (en) | 1998-04-14 | 1999-10-14 | Mitsuru Shiraishi | Composition for preventing or treating ischemic disease |
DE69903458T2 (de) | 1998-09-25 | 2003-07-10 | Warner Lambert Co | Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin |
US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
BR0111207A (pt) | 2000-05-31 | 2003-04-01 | Warner Lambert Co | Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos |
WO2002049630A2 (en) * | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
WO2003009805A2 (en) | 2001-07-23 | 2003-02-06 | Brigham And Women's Hospital, Inc. | Analgesic methods using endothelin receptor ligands |
US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
US20030229004A1 (en) | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
US8217010B2 (en) * | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
US20040138121A1 (en) | 2002-10-24 | 2004-07-15 | Anil Gulati | Method and composition for preventing and treating solid tumors |
EP1819367B1 (en) | 2004-11-22 | 2013-11-20 | The Board Of Trustees Of The University Of Illinois | Use of the endothelin etb receptor agonists irl-1620 in tumor imaging |
CA2598439A1 (en) * | 2005-02-22 | 2006-08-31 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
JP5306208B2 (ja) | 2006-08-31 | 2013-10-02 | スペクトラム ファーマシューティカルズ インコーポレイテッド | エンドセリンアゴニストの投与による放射線療法への腫瘍細胞の感作 |
-
2006
- 2006-08-02 US US11/461,961 patent/US20070032422A1/en not_active Abandoned
-
2007
- 2007-07-20 WO PCT/US2007/074036 patent/WO2008016793A2/en active Application Filing
- 2007-07-20 DK DK07799742.7T patent/DK2046323T3/da active
- 2007-07-20 CA CA2658340A patent/CA2658340C/en active Active
- 2007-07-20 MX MX2009001233A patent/MX2009001233A/es active IP Right Grant
- 2007-07-20 RU RU2009107085/14A patent/RU2407527C2/ru not_active IP Right Cessation
- 2007-07-20 ES ES07799742T patent/ES2402232T3/es active Active
- 2007-07-20 EP EP07799742A patent/EP2046323B1/en active Active
- 2007-07-20 BR BRPI0715521-2A patent/BRPI0715521A2/pt not_active IP Right Cessation
- 2007-07-20 EP EP12153542A patent/EP2450037A1/en not_active Withdrawn
- 2007-07-20 CN CN2007800288089A patent/CN101522186B/zh not_active Expired - Fee Related
- 2007-07-20 KR KR1020097001590A patent/KR101507178B1/ko active IP Right Grant
- 2007-07-20 JP JP2009522936A patent/JP2009545609A/ja active Pending
- 2007-08-01 AR ARP070103398A patent/AR062177A1/es not_active Application Discontinuation
- 2007-08-01 TW TW96128166A patent/TWI469776B/zh active
-
2009
- 2009-01-05 ZA ZA200900017A patent/ZA200900017B/xx unknown
- 2009-02-01 IL IL196825A patent/IL196825A/en not_active IP Right Cessation
- 2009-02-20 US US12/390,376 patent/US8030278B2/en not_active Expired - Lifetime
- 2009-02-27 NO NO20090915A patent/NO20090915L/no not_active Application Discontinuation
- 2009-10-09 HK HK09109362.2A patent/HK1129601A1/xx unknown
-
2011
- 2011-08-29 US US13/220,358 patent/US8440620B2/en not_active Expired - Lifetime
-
2012
- 2012-12-11 US US13/711,519 patent/US8729023B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
IL196825A0 (en) | 2011-08-01 |
KR20090034355A (ko) | 2009-04-07 |
TWI469776B (zh) | 2015-01-21 |
CN101522186A (zh) | 2009-09-02 |
US20110315575A1 (en) | 2011-12-29 |
US8030278B2 (en) | 2011-10-04 |
DK2046323T3 (da) | 2013-04-22 |
ZA200900017B (en) | 2009-11-25 |
HK1129601A1 (en) | 2009-12-04 |
IL196825A (en) | 2015-08-31 |
MX2009001233A (es) | 2009-02-12 |
US20090155206A1 (en) | 2009-06-18 |
NO20090915L (no) | 2009-02-27 |
US20130102543A1 (en) | 2013-04-25 |
TW200820965A (en) | 2008-05-16 |
WO2008016793A2 (en) | 2008-02-07 |
US8440620B2 (en) | 2013-05-14 |
WO2008016793A3 (en) | 2008-07-31 |
JP2009545609A (ja) | 2009-12-24 |
EP2450037A1 (en) | 2012-05-09 |
ES2402232T3 (es) | 2013-04-30 |
CA2658340C (en) | 2015-11-24 |
US8729023B2 (en) | 2014-05-20 |
KR101507178B1 (ko) | 2015-03-30 |
CN101522186B (zh) | 2013-06-05 |
AR062177A1 (es) | 2008-10-22 |
CA2658340A1 (en) | 2008-02-07 |
BRPI0715521A2 (pt) | 2013-06-25 |
US20070032422A1 (en) | 2007-02-08 |
EP2046323B1 (en) | 2013-02-13 |
RU2407527C2 (ru) | 2010-12-27 |
EP2046323A2 (en) | 2009-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sun et al. | Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer | |
Moserle et al. | Side population and cancer stem cells: therapeutic implications | |
RU2009107085A (ru) | Способы, композиции и изделия, способствующие лечению рака | |
Ren et al. | Marine natural products: A potential source of anti-hepatocellular carcinoma drugs | |
NZ572012A (en) | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines | |
US20080125380A1 (en) | Fatty acid-anticancer conjugates and uses thereof | |
CA2502848A1 (en) | Use of irl-1620 and paclitaxel for preventing and treating breast tumors | |
CN101965192A (zh) | 改善的抗肿瘤治疗 | |
KR102413412B1 (ko) | 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도 | |
JP2009545609A5 (ru) | ||
Yukawa et al. | Direct cytotoxicity of Lentinula edodes mycelia extract on human hepatocellular carcinoma cell line | |
Bao et al. | Apoptosis-inducing effects of lentinan on the proliferation of human bladder cancer T24 cells. | |
RU2009111605A (ru) | Сенсибилизация опухолевых клеток к лучевой терапии посредством введения агонистов эндотелина | |
Sun et al. | Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells | |
Attia et al. | The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells | |
Zhu et al. | The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells | |
Holmberg et al. | Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein | |
RU2010140611A (ru) | Комбинированное применение производных холестанола | |
CN110694070A (zh) | 细胞毒类抗肿瘤药物在制备肿瘤相关组织中的应用 | |
US20190183860A1 (en) | Method for the treatment of atg4-related disorders | |
Alkafaas et al. | DEXAMETHASONE IMPROVES THE RESPONSIVENESS OF HEPATOMA CELLS FOR BOTH FREE AND SOLVENT CONTAINING PACLITAXEL IN VITRO. | |
RU2009141845A (ru) | Способы и композиции для содействия в лечении злокачественных опухолей | |
CN102872000A (zh) | 紫杉化合物类单烷氧基衍生物在制备抗肿瘤药物中的用途 | |
Wagenblast et al. | Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck | |
Fauzee et al. | Novel hydrophilic taxane analogues inhibit growth of cancer cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160721 |